Surface Oncology has started a Phase I trial of SRF373 (NZV930) for the treatment of various types of cancer.
The first-in-human trial is designed to investigate the safety, tolerability, and preliminary anti-tumour activity of NZV930 as a single agent and in combination with other cancer immunotherapies.
Its initial dose-escalation portion will comprise patients with triple negative breast cancer, ovarian cancer, microsatellite stable colon cancer, pancreatic cancer, non-small cell lung cancer, and renal cell carcinoma.
The trial is being led by Novartis, which received a worldwide exclusive licence to develop and commercialise NZV930 under its broad strategic collaboration with Surface.
As part the collaboration, Surface is expected to receive development and sales milestone payments for NZV930, as well as tiered royalties.
“We believe the profile of NZV930 is compelling and targeting adenosine reduction could play an important role in the treatment of patients suffering with a variety of types of cancer.”
Surface Oncology chief medical officer Rob Ross said: “We believe the profile of NZV930 is compelling and targeting adenosine reduction could play an important role in the treatment of patients suffering with a variety of types of cancer.”
SRF373 is a fully human antibody designed to target CD73, an enzyme overexpressed by many tumours that is critical to the production of extracellular adenosine, which in turn restricts immune cell function and the ability of the immune system to recognise and attack tumours.
In a number of preclinical studies, NZV930 demonstrated potent CD73 enzymatic inhibition, thereby resulting in a reduction of adenosine and increased T-cell activity.
NZV930 also represents the second immunotherapies developed by Surface to advance into the clinic this year.